PL378566A1 - Ligandy dla białek wiążących TGF-beta i ich zastosowania - Google Patents

Ligandy dla białek wiążących TGF-beta i ich zastosowania

Info

Publication number: PL378566A1
Authority: PL; Poland
Prior art keywords: tgf; complex; beta binding; ligands; binding proteins
Prior art date: 2003-03-14

Application number

PL378566A

Other languages

English (en)

Inventor

David G. Winkler

John Latham

John Skonier

Diana Shpektor

Trenton Hayes

James Geoghegan

Original Assignee

Celltech R & D, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-14

Filing date

2004-03-12

Publication date

2006-05-02

2004-03-12 Application filed by Celltech R & D, Inc. filed Critical Celltech R & D, Inc.

2006-05-02 Publication of PL378566A1 publication Critical patent/PL378566A1/pl

Links

ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title abstract 4
108091008324 binding proteins Proteins 0.000 title abstract 3
102000014914 Carrier Proteins Human genes 0.000 title 1
239000003446 ligand Substances 0.000 title 1
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 3
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 3
102000019307 Sclerostin Human genes 0.000 abstract 2
108050006698 Sclerostin Proteins 0.000 abstract 2
239000005557 antagonist Substances 0.000 abstract 2
102000023732 binding proteins Human genes 0.000 abstract 2
230000018678 bone mineralization Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
102000006533 chordin Human genes 0.000 abstract 1
108010008846 chordin Proteins 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
102000045246 noggin Human genes 0.000 abstract 1
108700007229 noggin Proteins 0.000 abstract 1
238000007423 screening assay Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Biochemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Peptides Or Proteins (AREA)

PL378566A 2003-03-14 2004-03-12 Ligandy dla białek wiążących TGF-beta i ich zastosowania PL378566A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US45525303P	2003-03-14	2003-03-14

Publications (1)

Publication Number	Publication Date
PL378566A1 true PL378566A1 (pl)	2006-05-02

Family

ID=33029975

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL378566A PL378566A1 (pl)	2003-03-14	2004-03-12	Ligandy dla białek wiążących TGF-beta i ich zastosowania
PL04720380T PL1608399T3 (pl)	2003-03-14	2004-03-12	Kompleks sklerostyny i nogginy lub chordyny, oraz czynniki modulujące tworzenie tego kompleksu

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL04720380T PL1608399T3 (pl)	2003-03-14	2004-03-12	Kompleks sklerostyny i nogginy lub chordyny, oraz czynniki modulujące tworzenie tego kompleksu

Country Status (15)

Country	Link
US (1)	US7226902B2 (pl)
EP (1)	EP1608399B1 (pl)
JP (1)	JP4660471B2 (pl)
AT (1)	ATE540977T1 (pl)
AU (1)	AU2004222317B2 (pl)
CA (1)	CA2519131C (pl)
CY (1)	CY1112797T1 (pl)
DK (1)	DK1608399T3 (pl)
ES (1)	ES2379689T3 (pl)
MX (1)	MXPA05009805A (pl)
NZ (1)	NZ542587A (pl)
PL (2)	PL378566A1 (pl)
PT (1)	PT1608399E (pl)
SI (1)	SI1608399T1 (pl)
WO (1)	WO2004082608A2 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE481487T1 (de)	1998-11-27	2010-10-15	Ucb Sa	Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
CA2529623A1 (en)	2003-06-16	2005-02-17	Celltech R & D, Inc.	Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) *	2003-09-22	2013-06-11	University Of Connecticut	Sclerostin and the inhibition of WNT signaling and bone formation
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
US7592429B2 (en) *	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
WO2007028212A1 (en) *	2005-09-08	2007-03-15	Apollo Life Sciences Limited	Noggin and chimeric molecules thereof
EP2069558B1 (en)	2006-10-02	2013-05-01	Sea Lane Biotechnologies,llc.	Design and construction of diverse synthetic peptide and polypeptide libraries
EP2460828A3 (en) *	2006-11-10	2012-08-08	UCB Pharma, S.A.	Antibodies and diagnostics
EP2423226A3 (en) *	2006-11-10	2012-05-30	Amgen Inc.	Antibody-based diagnostics and therapeutics
EP2114435A1 (en) *	2007-02-02	2009-11-11	Novartis AG	Modulators of sclerostin binding partners for treating bone-related disorders
CL2008002775A1 (es)	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CN101896201A (zh) *	2007-12-14	2010-11-24	安进公司	使用抗硬骨素抗体治疗骨折的方法
JP6018753B2 (ja) *	2008-11-13	2016-11-02	ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅＧｅｎｅｒａｌＨｏｓｐｉｔａｌＣｏｒｐｏｒａｔｉｏｎ	Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
KR101163171B1 (ko) *	2009-01-20	2012-07-19	(주)케어젠	노긴?유래 펩타이드 및 그의 용도
SMT202000095T1 (it)	2010-05-14	2020-03-13	Amgen Inc	Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
EA201391248A1 (ru)	2011-03-01	2014-05-30	Эмджен Инк.	Биспецифические связывающие агенты
AP3981A (en)	2011-03-25	2017-01-05	Amgen Inc	Anti - sclerostin antibody crystals and formulations thereof
SI2739311T1 (en)	2011-08-04	2018-07-31	Amgen Inc.	Method for the treatment of bone defect defects
EP3712168A3 (en)	2011-12-28	2020-10-14	Amgen Inc.	Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
AU2013285488B2 (en)	2012-07-05	2018-03-22	Ucb Pharma S.A.	Treatment for bone diseases
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
MA41142A (fr)	2014-12-12	2017-10-17	Amgen Inc	Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en)	2016-03-10	2016-04-27	Ucb Biopharma Sprl	Pharmaceutical formulation
US10961305B2 (en)	2016-12-21	2021-03-30	Mereo Biopharma 3 Limited	Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
EP3774879B1 (en)	2018-03-30	2026-01-28	Amgen Inc.	C-terminal antibody variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5846770A (en) *	1994-11-22	1998-12-08	Genetics Institute, Inc.	DNA molecules encoding human chordin
CA2220912A1 (en)	1995-06-05	1996-12-12	Gregg A. Hastings	Human ccn-like growth factor
US5989909A (en)	1997-09-26	1999-11-23	Millennium Biotherapeutics, Inc.	Huchordin and uses thereof
US6117911A (en) *	1997-04-11	2000-09-12	Neorx Corporation	Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6075007A (en) *	1997-07-17	2000-06-13	Regeneron Pharmaceuticals, Inc.	Modified noggin polypeptide and compositions
ATE440143T1 (de)	1998-03-30	2009-09-15	Dow Agrosciences Llc	Änderung der fettsäure-zusammensetzung in pflanzen durch expression einer aspergillus nidulans delta-9 coa desaturase
ATE481487T1 (de)	1998-11-27	2010-10-15	Ucb Sa	Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
JP2003525611A (ja) *	2000-03-02	2003-09-02	アムジェンインコーポレーテッド	コルディン様−２分子およびその使用

2004
- 2004-03-12 MX MXPA05009805A patent/MXPA05009805A/es active IP Right Grant
- 2004-03-12 EP EP04720380A patent/EP1608399B1/en not_active Expired - Lifetime
- 2004-03-12 AT AT04720380T patent/ATE540977T1/de active
- 2004-03-12 US US10/799,162 patent/US7226902B2/en not_active Expired - Fee Related
- 2004-03-12 DK DK04720380.7T patent/DK1608399T3/da active
- 2004-03-12 PT PT04720380T patent/PT1608399E/pt unknown
- 2004-03-12 WO PCT/US2004/007565 patent/WO2004082608A2/en not_active Ceased
- 2004-03-12 PL PL378566A patent/PL378566A1/pl unknown
- 2004-03-12 CA CA2519131A patent/CA2519131C/en not_active Expired - Fee Related
- 2004-03-12 JP JP2006507118A patent/JP4660471B2/ja not_active Expired - Fee Related
- 2004-03-12 AU AU2004222317A patent/AU2004222317B2/en not_active Ceased
- 2004-03-12 ES ES04720380T patent/ES2379689T3/es not_active Expired - Lifetime
- 2004-03-12 SI SI200431852T patent/SI1608399T1/sl unknown
- 2004-03-12 PL PL04720380T patent/PL1608399T3/pl unknown
- 2004-03-12 NZ NZ542587A patent/NZ542587A/en not_active IP Right Cessation
2012
- 2012-04-09 CY CY20121100348T patent/CY1112797T1/el unknown

Also Published As

Publication number	Publication date
WO2004082608A2 (en)	2004-09-30
SI1608399T1 (sl)	2012-05-31
US20050085418A1 (en)	2005-04-21
MXPA05009805A (es)	2006-04-18
DK1608399T3 (da)	2012-04-02
ATE540977T1 (de)	2012-01-15
PT1608399E (pt)	2012-04-13
WO2004082608A9 (en)	2005-03-17
JP2006522103A (ja)	2006-09-28
EP1608399B1 (en)	2012-01-11
EP1608399A2 (en)	2005-12-28
AU2004222317A1 (en)	2004-09-30
JP4660471B2 (ja)	2011-03-30
ES2379689T3 (es)	2012-04-30
CA2519131A1 (en)	2004-09-30
PL1608399T3 (pl)	2012-09-28
NZ542587A (en)	2008-05-30
CA2519131C (en)	2014-07-08
AU2004222317B2 (en)	2010-08-19
CY1112797T1 (el)	2016-02-10
WO2004082608A3 (en)	2005-01-20
US7226902B2 (en)	2007-06-05

Publication	Publication Date	Title
PL378566A1 (pl)	2006-05-02	Ligandy dla białek wiążących TGF-beta i ich zastosowania
CY1124802T1 (el)	2022-11-25	Δεσμευτικοι παραγοντες σκληροστινης
MEP3108A (xx)	2010-02-10	Kompozicije i postupci za povećanje mineralizacije kostiju
MEP2808A (xx)	2010-02-10	Antitijela specifična za sklerositin i metode za povećanje mineralizacije kostiju
MY174493A (en)	2020-04-23	Binding agents
MX2007008017A (es)	2007-09-12	Polipeptidos que se ligan a br3 y usos de los mismos.
EA200801621A1 (ru)	2008-12-30	Антитела, направленные на her-3, и их применение
EA200700847A1 (ru)	2007-10-26	Материалы, связывающие прионные белки, и способы их применения
TW200745159A (en)	2007-12-16	IL-6 binding proteins
WO2006087163A3 (en)	2007-04-19	Novel in vitro methods for studying receptors recognizing volatile compounds
EA200800205A1 (ru)	2008-08-29	Кальций-пептидный компонент
WO2003060067A3 (en)	2004-07-29	P85-alpha nucleic acids, polypeptides and related methods
EA200500624A1 (ru)	2005-10-27	Промотор для il-18bp, его получение и применение
WO2006008266A3 (en)	2006-08-03	Factor xi-binding proteins
HK1151803B (en)	2015-08-28	Sclerostin binding agents
WO2004070347A3 (en)	2004-12-16	Screening for modulators of fat storage
TW200718711A (en)	2007-05-16	Polypeptides that bind BR3 and uses thereof
UA115859C2 (uk)	2018-01-10	Розчинний поліпептид, який зв'язує активін а, та композиція, що його містить
WO2007050554A3 (en)	2009-04-30	Methods for identifying compounds that modulate phb domain protein activity and compositions thereof
WO2005040208A3 (en)	2005-10-20	Peptides derived from heat shock proteins binding toll-like receptors 2 and 4 and their use
SE0401166D0 (sv)	2004-05-03	Method for protein protection